CYP3A5∗3 and POR∗28 genetic variants influence the required dose of tacrolimus in heart transplant recipients

Therapeutic Drug Monitoring

Volumn 36, Issue 6, 2014, Pages 710-715

  Lesche, Dorothea ^a,b   Sigurdardottir, Vilborg ^c   Setoud, Raschid ^c   Oberhänsli, Markus ^c   Carrel, Thierry ^c   Fiedler, Georg ^a   Largiadèr, Carlo ^a   Mohacsi, Paul ^c   Sistonen, Johanna ^a  

^a UNIVERSITY OF BERN   (Switzerland)

^b UNIVERSITY OF BERN   (Switzerland)

^c BERN UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

ciclosporin; heart transplantation; pharmacogenomics; tacrolimus

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN A; CYTOCHROME P450 3A5; CYTOCHROME P450 REDUCTASE; EVEROLIMUS; METHYLPREDNISOLONE; MYCOPHENOLATE MOFETIL; PREDNISONE; RAPAMYCIN; TACROLIMUS; THYMOCYTE ANTIBODY; CYTOCHROME P450 3A; IMMUNOSUPPRESSIVE AGENT; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE FERRIHEMOPROTEIN REDUCTASE;

ADULT; ARTICLE; DRUG BLOOD LEVEL; FEMALE; GENETIC ASSOCIATION; GENETIC MARKER; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HEART TRANSPLANTATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PHARMACOGENOMICS; PRIORITY JOURNAL; ADVERSE EFFECTS; COHORT ANALYSIS; DOSE RESPONSE; FOLLOW UP; GENETICS; GRAFT RECIPIENT; GRAFT REJECTION; RETROSPECTIVE STUDY;

ADULT; COHORT STUDIES; CYTOCHROME P-450 CYP3A; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; GENETIC VARIATION; GRAFT REJECTION; HEART TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; NADPH-FERRIHEMOPROTEIN REDUCTASE; RETROSPECTIVE STUDIES; TACROLIMUS; TRANSPLANT RECIPIENTS;

EID: 84930081898     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0000000000000080     Document Type: Article

References (36)

1. Thervet E, Anglicheau D, Legendre C, et al. Role of pharmacogenetics of immunosuppressive drugs in organ transplantation. Ther Drug Monit. 2008; 30: 143-150
2. Elens L, Bouamar R, Shuker N, et al. Clinical implementation of pharmacogenetics in kidney transplantation: CNIs in the starting blocks. Br J Clin Pharmacol. 2014; 77: 715-728
3. Hesselink DA, Bouamar R, Elens L, et al. The role of pharmacogenetics in the disposition of and response to tacrolimus in solid organ transplantation. Clin Pharmacokinet. 2014; 53: 123-139
4. Stehlik J, Edwards LB, Kucheryavaya AY, et al. The Registry of the International Society for Heart and Lung Transplantation: 29th official adult heart transplant report 2012. J Heart Lung Transplant. 2012; 31: 1052-1064
5. Monchaud C, Marquet P. Pharmacokinetic optimization of immunosuppressive therapy in thoracic transplantation: part I. Clin Pharmacokinet. 2009; 48: 419-462
6. Tang HL, Xie HG, Yao Y, et al. Lower tacrolimus daily dose requirements and acute rejection rates in the CYP3A5 nonexpressers than expressers. Pharmacogenet Genomics. 2011; 21: 713-720
7. Terrazzino S, Quaglia M, Stratta P, et al. The effect of CYP3A5 6986A.G and ABCB1 3435C.T on tacrolimus dose-Adjusted trough levels and acute rejection rates in renal transplant patients: a systematic review and meta-Analysis. Pharmacogenet Genomics. 2012; 22: 642-645
8. Zhu HJ, Yuan SH, Fang Y, et al. The effect of CYP3A5 polymorphism on dose-Adjusted cyclosporine concentration in renal transplant recipients: a meta-Analysis. Pharmacogenomics J. 2011; 11: 237-246
9. Fredericks S, Moreton M, Reboux S, et al. Multidrug resistance gene-1 (MDR-1) haplotypes have a minor influence on tacrolimus dose requirements. Transplantation. 2006; 82: 705-708
10. Haufroid V, Mourad M, Van Kerckhove V, et al. The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients. Pharmacogenetics. 2004; 14: 147-154
11. Zheng H, Webber S, Zeevi A, et al. Tacrolimus dosing in pediatric heart transplant patients is related to CYP3A5 and MDR1 gene polymorphisms. Am J Transplant. 2003; 3: 477-483
12. Elens L, Bouamar R, Hesselink DA, et al. A new functional CYP3A4 intron 6 polymorphism significantly affects tacrolimus pharmacokinetics in kidney transplant recipients. Clin Chem. 2011; 57: 1574-1583
13. Elens L, van Schaik RH, Panin N, et al. Effect of a new functional CYP3A4 polymorphism on calcineurin inhibitors dose requirements and trough blood levels in stable renal transplant patients. Pharmacogenomics. 2011; 12: 1383-1396
14. Wang D, Guo Y, Wrighton SA, et al. Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs. Pharmacogenomics J. 2011; 11: 274-286
15. Gijsen VM, van Schaik RH, Elens L, et al. CYP3A422 and CYP3A combined genotypes both correlate with tacrolimus disposition in pediatric heart transplant recipients. Pharmacogenomics. 2013; 14: 1027-1036
16. Benkali K, Premaud A, Picard N, et al. Tacrolimus population pharmacokinetic-pharmacogenetic analysis and Bayesian estimation in renal transplant recipients. Clin Pharmacokinet. 2009; 48: 805-816
17. de Jonge H, Metalidis C, Naesens M, et al. The P450 oxidoreductase 28 SNP is associated with low initial tacrolimus exposure and increased dose requirements in CYP3A5-expressing renal recipients. Pharmacogenomics. 2011; 12: 1281-1291
18. Evans WE, Relling MV. Moving towards individualized medicine with pharmacogenomics. Nature. 2004; 429: 464-468
19. Stewart S, Winters GL, Fishbein MC, et al. Revision of the 1990 working formulation for the standardization of nomenclature in the diagnosis of heart rejection. J Heart Lung Transplant. 2005; 24: 1710-1720
20. Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009; 150: 604-612
21. Diaz-Molina B, Tavira B, Lambert JL, et al. Effect of CYP3A5, CYP3A4, and ABCB1 genotypes as determinants of tacrolimus dose and clinical outcomes after heart transplantation. Transplant Proc. 2012; 44: 2635-2638
22. Gijsen V, Mital S, van Schaik RH, et al. Age and CYP3A5 genotype affect tacrolimus dosing requirements after transplant in pediatric heart recipients. J Heart Lung Transplant. 2011; 30: 1352-1359
23. Excoffier L, Lischer HE. Arlequin suite ver 3.5: a new series of programs to perform population genetics analyses under Linux and Windows. Mol Ecol Resour. 2010; 10: 564-667
24. Lewontin RC. The interaction of selection and linkage. I. General considerations; heterotic models. Genetics. 1964; 49: 49-67
25. Excoffier L, Laval G, Balding D. Gametic phase estimation over large genomic regions using an adaptive window approach. Hum Genomics. 2003; 1: 7-19
26. The 1000 Genomes Project. Available at: http://www.1000genomes.org/. Accessed August 27, 2013
27. Sakurai A, Onishi Y, Hirano H, et al. Quantitative structure-Activity relationship analysis and molecular dynamics simulation to functionally validate nonsynonymous polymorphisms of human ABC transporter ABCB1 (P-glycoprotein/MDR1). Biochemistry. 2007; 46: 7678-7693
28. Kniepeiss D, Renner W, Trummer O, et al. The role of CYP3A5 genotypes in dose requirements of tacrolimus and everolimus after heart transplantation. Clin Transplant. 2011; 25: 146-150
29. Zanger UM, Schwab M. Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Ther. 2013; 138: 103-141
30. Huang N, Agrawal V, Giacomini KM, et al. Genetics of P450 oxidoreductase: sequence variation in 842 individuals of four ethnicities and activities of 15 missense mutations. Proc Natl Acad Sci U S A. 2008; 105: 1733-1738
31. Miller WL, Agrawal V, Sandee D, et al. Consequences of POR mutations and polymorphisms. Mol Cell Endocrinol. 2011; 336: 174-179
32. Gijsen VM, van Schaik RH, Soldin OP, et al. P450 oxidoreductase 28 (POR28) and tacrolimus disposition in pediatric kidney transplant recipients-A pilot study. Ther Drug Monit. 2014; 36: 152-158
33. Zhang JJ, Zhang H, Ding XL, et al. Effect of the P450 oxidoreductase28 polymorphism on the pharmacokinetics of tacrolimus in Chinese healthy male volunteers. Eur J Clin Pharmacol. 2013; 69: 807-812
34. Chu XM, Hao HP, Wang GJ, et al. Influence of CYP3A5 genetic polymorphism on cyclosporine A metabolism and elimination in Chinese renal transplant recipients. Acta Pharmacol Sin. 2006; 27: 1504-1508
35. Fanta S, Niemi M, Jonsson S, et al. Pharmacogenetics of cyclosporine in children suggests an age-dependent influence of ABCB1 polymorphisms. Pharmacogenet Genomics. 2008; 18: 77-90
36. Hesselink DA, van Schaik RH, van der Heiden IP, et al. Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus. Clin Pharmacol Ther. 2003; 74: 245-254